Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Res. 2018 Nov 1;79(1):251–262. doi: 10.1158/0008-5472.CAN-18-2918

Figure 1: Schematic of nutlin-based PROTAC and its component ligands.

Figure 1:

(A) structure of the BRD4/BET inhibitor, JQ1; (B) structure of idasanutlin (RG7388), an MDM2 antagonist; (C) structure of A1874, an MDM2-recruiting, BRD4-degrading PROTAC.